The referred compounds were tested in antibacterial (Escherichia coli, Bacillus megaterium), antifungal (Mycotypha microspora, Eurotium rubrum, and Microbotryum violaceum), and antialgal (Chlorella fusca) assays as described before [17, 18] . The inhibition of the following panel of proteases inhibition assays (chymotrypsin, trypsin, the protease elastase HLE, papain, porcine cease and acetylcholine esterase) were performed according to Neumann et al. [19] . Compounds were tested for protein kinase inhibition assays (DYRK1A and CDK5) according to Bettayeb et al. [20] . The triglyceride accumulation inhibition in the 3T3-L1 murine adipocytes assay was performed as described by Shimokawa et al. [21] . Cytotoxic activity assay against a panel of three cancer cell lines, NCI-H460, MCF7 and SF268 at the 100 µM level was performed according to Saroglou et al. [22] and Monks et al. [23] . Compounds were tested for antiplasmodial activity against Plasmodium berghei liver stages as described by Ploemen et al. [24] . Inhibition of the viral HIV-1-and HIV-2-induced cytopathogenic effect in MT-4 cells assays was performed according to Pannecouque et al. [25] and Zhan et al. [26] . Severe Acute Respiratory Syndrome coronavirus (SARS) assays were performed according to Kumaki et al. [27] , the Herpes Simplex Virus-2 (HSV-2) activity assays according to Harden et al. [28] , the Respiratory Syncytial virus (RSV) activity assays according to Barnard et al. [29, 30] , the Influenza viruses A and B (Flu A and B) activity assays as described by Sidwell and Smee [31] , and the Hepatitis B virus was performed according to Sells et al. [32] and Korba and Gerin [33] . The activity assays against two strains of antibiotic resistant Mycobacterium tuberculosis were performed according to Bauer et al. [34] . The methodology for the inhibition of the NF-κB protein complex is described by Schumacher et al. [35] . The compounds were tested against a panel of antidiabetic activity assays as described by Marrapodi and Chiang [36] , Dey et al. [37] and Seale et al. [38] . The binding assays against a panel of 44 psychoactive receptors (activity considered with at least 50% inhibition at the 10 μM level against 5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 1E , 5-HT 2A , 5-HT 2B , 5-HT 2C , 5-HT 3 , 5-HT 5A , 5-HT 6 , 5-HT 7 , α 1A , α 1B , α 1D , α 2A , α 2B , α 2C , β 1 , β 2 , β 3 , BZP Rat Brain Site, D 1  


Section:methodology for the performed biological assays